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Abstract 
Introduction: Infection with hHigh-risk types of HPV (HR-HPV) isare the main 
aetiological agent forcause of invasive cervical cancer (ICC) from which there are 
>270,000 deaths per annum world-wide with over 85% of these occurring in low-
resource countries. Ablative and excisional treatment modalities are restricted for use 
with high-grade pre-cancerous cervical disease with HPV infection and low-grade 
dysplasia is currently managed by a watch-and-wait policy.  
Areas Covered: A variety of different pharmacological approaches have been 
investigated as non-destructive alternatives for the treatment of HR-HPV infection and 
associated dysplasia. . In this review, the authorsThese are discussed developments in 
this area dealing with efficacy, ease-of-use (physician or self-applied), systemic or 
locally applied, side-effects, cost  and finally anyand associated risks. The main focus 
will be discussion of the perceived impact on current clinical practice of a self-applied, 
effective and safe pharmacological anti-HPV treatment.   
Expert Opinion: Current prophylactic HPV vaccines are expensive, only protect 
against the two most prevalent malignant disease-associated HPV types and have little 
effect in women who are already infected. There are therapeutic vaccines under 
development but these are also HPV type-restricted. At present, the developed nations 
use national cytology screening and surgical procedures to treat only women identified 
with HPV-related high-grade dysplastic disease. However, since HPV testing is rapidly 
replacing cytology as the test-of-choice, a suitable topically-applied and low-cost 
antiviral treatment could be an ideal solution for treatment of HPV infection per se with 
test-of-cure carried out by repeat HPV testing. Cytology would only then be necessary 
for women who remained HPV positive. Although of significant benefit in the 
developed countries, this could revolutionise the management of this disease in the 
developing nations which lack both the infrastructure and resources to establish 
national cytology screening programs. Combining such a treatment with self-sampled 
HPV testing could provide a very cost-effective solution to the huge burden of HPV 
related disease in such low-resource settings.   
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1. Introduction 
Infection with high-risk (HR) types of HPV is now well established as the main 
aetiological agent for invasive cervical cancer (ICC)1-3 and globally there are >270,000 
deaths from this disease per annum with over 85% of these occurring in low resource 
settings where it comprises >23% of all female malignancies4, 5. The development of 
ICC can take 10-20 years and is preceded by   oncogenic HPV related pre-invasive 
pathologies which are characterised as either low-grade (CIN1) or high-grade cervical 
intraepithelial neoplasia (CIN2/3)1 . Such lesions can be are typically screen detected 
by cervical cytology testing where they are diagnosed as either borderline atypical 
squamous cells of undetermined significance (ASCUS), low-grade squamous 
intraepithelial lesions (LSIL) or high-grade squamous intraepithelial lesions (HSIL)6 
(See Figure 1). If cervical cytology is abnormal, screening programmes 
warrantedrecommend diagnostic and management guidelines. , Diagnosis involves 
ccolposcopy and when the is then performed where diagnosis of high grade CIN grade 
is subsequently confirmed by biopsy, treatment is mandated. and histopathology. 
The reduction in ICC related mortality in the developed world has been largely 
dependent on organised cytology screening and similar trends in cervical cancer 
mortality have been achieved by the practice of organised single screen and treat in low 
resource settings 7. However, in the majority of the poorer nations, lack of resources 
and health education means that most pre-invasive cervical disease remains 
undiagnosed and untreated.  Thus, where resources are limited, low-cost screening and 
alternative treatment options are clearly a high priority. 
Current treatment options in clinical practice are either by ablative (destructive) 
or excisional modalities which have similar success rates but have different morbidities 
8. In the developed nations, Large Loop Excision of the Transformation Zone LLETZ 
(aka loop electrosurgical excision procedure – LEEP 9) is used in the majority of 
colposcopy clinics. Over 80% of these procedures are performed under local analgesia 
and the whole of the transformation zone is available for subsequent histological 
examination. Although highly effective (80-95%), this procedure is associated with a 
risk of primary/secondary haemorrhage, prolonged vaginal discharge, infection and a 
risk of preterm delivery in subsequent pregnancies which can be problematic in low 
resource countries 10, 11.  Ablative cold coagulation and cryotherapy are often advocated 
for use in these settings since these are low cost, require minimal infrastructure and can 
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be carried out by trained non-medical health professionals. However, some studies have 
suggested that these treatments have a higher failure rate when compared to other 
modalities 8, 12.  
AIt is very clear that, whilst effective, ablative and destructive approaches to 
treatment have their limitations and in the small minority of cases can lead to persistent 
disease requiring more radical treatment which might ultimately require hysterectomy. . 
Due to the associated morbidity and potential complications they are restricted for use 
with high-grade disease and can only be repeated a finite number of times until 
hysterectomy is inevitable. Furthermore, implementation of these procedures requires 
appropriately trained medical staff and facilities which are often not available in low-
resource settings. Moreover, any treatment associated complications are also much 
more difficult to manage in such locations.   
Prevention is an obvious solution to these problems and the two currently 
available prophylactic vaccines Cervarix® and Gardasil® have now been implemented 
in many of the developed nations 13 although limitations of their use are HR-HPV 16/18 
type restriction and high cost. Even though a prophylactic nonavalent vaccine is under 
development it is still likely to be expensive.14 SinceFurthermore, since thesese are 
prophylactics, an effective pharmacotherapy for HPV infection and any associated 
underlying dysplasia would be an ideal solution for women already infected with HPV. 
Thus implementation of a well-tolerated and safe non-destructive treatment modality 
would permit this to be used against HPV infection per se, in addition to low-grade 
disease, for which there are currently no treatment options. This would be particularly 
advantageous in low resource settings where low-cost HPV tests, such as Care HPV 
(Qiagen), combined with self-sampling, could provide an alternative to cytology for the 
basis of treatment decisions with test-of-cure carried out by follow-up repeat HPV 
testing 15. Those women with persistent HPV infection could then either be re-treated or 
referred for conventional colposcopy followed by surgery if this was deemed necessary. 
However, for such a pharmacological treatment to be implemented, it would clearly 
need to be reasonably priced and have comparable success rates to current surgical 
procedures.  
There are a variety of non-surgical approaches which have been evaluated in 
clinical trials for the treatment of HPV related cervical dysplasia although in 2004 these 
were not recommended due to side-effects and limited efficacy 16. However, recent 
improvements in their application combined with the development of new modalities 
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means some of these approaches have now “come-of-age” 17 and these will now b e 
discussed with respect to their ability to fulfil the aforementioned criteria.  
 
2. Photodynamic Therapy (PDT)  
PDT is a minimally invasive procedure which uses either topical or systemic treatment 
with a photo-sensitiser followed by exposure to light of an appropriate wavelength and 
it has been used to treat both low and high grade cervical dysplasia with varying 
degrees of success 18. Systemic photo-sensitisers, such as Photfrin®, can cause problems 
with non-specific dermal photosensitisation.  Aalthough a recent small series study, 
using the topical photo-sensitiser hexaminolevulinate, has reported high success rates of 
95% clearance of CIN lesions with 83% (5/6 patients) clearance of HPV16/1819. These 
findings clearly indicate that this procedure has considerable potential to provide an 
effective non-surgical treatment for both low and high-grade HPV related dysplasia, if 
proven in larger studies. However, since it is physician applied, with the attendant and 
equipment and cost implications, it is very unlikely to be used for the treatment of HPV 
infection or disease in low resource settings per se. This implies that PDT would thus 
be restricted to the treatment of histologically confirmed dysplasia. 
 
3. Cidofovir 
The antiviral drug cidofovir is currently licensed for the treatment HIV related CMV 
retinitis and it has been used extensively off-licence for the treatment of low-risk (LR) 
HPV laryngeal warts 20. It has also been used to treat HR-HPV related cervical 
dysplasia 21 and more recently with some success where 14/23 (>60%) of women with 
pre-treatment biopsy confirmed CIN2 were found to be histologically normal following 
3 physician-applied local applications of cidofovir 22. However, since this drug is both 
mutagenic 23 and carcinogenic in animals its use for the treatment of HPV related 
benign and pre-malignant pathologies has proved controversial 24. Given these 
concerns, it is not likely that the use of locally applied cidofovir would be approved for 
the treatment of cervical HPV infection per se even when low grade dysplasia is also 
present. Furthermore, at a cost of approximately $1000 for a 5 ml vial of 75 mg/ml it is 
also expensive which would limit its use in resource constrained settings.  
 
4. Imiquimod 
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The immune activator imiquimod does not have direct antiviral activity but activates 
cytokines which subsequently promote immunological clearance of virus 25. Although 
local application of this agent has been used extensively to treat LR-HPV related 
genital warts, its efficacy was found to be questionable in a recent systematic review26. 
In a study carried out in Taiwan, women who had been treated with surgery for cervical 
and vaginal dysplasia, but had persistent HPV infection both with and without 
dysplasia, were treated with locally applied 5% imiquimod cream for 6 weeks which 
showed 65% clearance of HPV infection 27. Moreover >60% clearance of cervical 
dysplasia was also reported but only in 4/6 patients. A very similar study, also carried 
out in Taiwan, used 5% imiquimod cream for 8 weeks and showed a 76% clearance of 
HPV presumably due to the longer treatment period 28. However, a comparison of 
imiquimod therapy to standard surgical intervention for CIN treatment concluded that 
disease recurrence was the same in both groups and yet side effects such as fever, 
fatigue, headache, myalgia, nausea, chills and vaginal discharge were considerably 
worse in women treated with imiquimod 29.  Compared to cidofovir, imiquimod is 
reasonably priced and there is no doubt that it is effective in some women. 
Furthermore, it can be self-applied although its efficacy is not better than surgical 
procedures and it can produce unpleasant side-effects for the duration of treatment 
limiting compliance. To illustrate, 39 (46%) of 84 women treated with 5% imiquimod 
for HPV-related vulval intraepithelial neoplasia (VIN), reported grade 3 or 4 adverse 
events 30.     
    
5. 5-Flurouracil (5-FU) 
5-FU is pyrimidine analogue cytotoxic agent used in the treatment of cancer and topical 
application of a 5% solution of this drug for 8 weeks over a 16 week period has been 
used to treat CIN2 31. This produced regression of disease in 96% of patients after 6 
months follow up although only 50% had normal pathology and were also negative for 
HPV. It is well known that 5-FU has very significant toxic side-effects associated with 
both local and systemic use and these effects can be difficult to predict demonstrating 
marked variations between individuals 32. Since 5-FU is so toxic, its application to the 
cervix was physician-applied and its reported efficacy against CIN2 and HPV was no 
better than current surgical procedures.  Given these observations and safety concerns, 
it is very clear that this drug would not be approved for the treatment of HPV infection 
per se or even low-grade disease in the general population.  
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6. Interferon 
Ten intra-lesional injections of 3mIU of the endogenous human antiviral protein 
interferon-alpha over 3-4 weeks were used to treat 45 cases of CIN1-3 and 30 of 
carcinoma in situ (CIS) 33. All women returned to normal cytology and were HPV 
negative which was maintained during a six year follow-up period. This study was a 
simple proof-of-concept with no control arm and yet, given the marked efficacy 
observed, it is curious that there have been no further more robust phase 2 studies 
carried out on this indication. This could be related to the need for direct intra-lesional 
injection and with interferon-alpha being a biological, it is veryquite expensive. 
Furthermore, systemic interferon does cause significant side-effects such as flu like 
symptoms and low mood. However, there are now microencapsulated forms of this 
drug available which can be used for direct topical application although it is very likely 
that cost will still be an issue 34.     
 
8. Therapeutic Vaccines 
Although not strictly pharmacotherapy, a variety of therapeutic HPV vaccines have 
been produced which are at various stages of clinical development and many of these 
are summarised in a recent review by Rosales and Rosales 35. One of the most 
interesting is the live vaccinia virus based MVA-E2 vaccine which was initially tested 
in Mexico where 36 women received direct intrauterine injection of the vaccine once 
weekly for 6 weeks. This produced a return to normal cytology in 85% of patents 
although HPV was still present in 50% of those treated 36. The same authors carried 
out a more comprehensive study of the efficacy of MVA-E2 on HPV related 
dysplastic lesions in 1176 women and 180 men by direct injection of the vaccine into 
the uterus, vulva, urethra or anus 37. The outcome was elimination of HPV DNA is 
83% of patients treated with 89% of women and 100% of men showing normal 
histology post-treatment. Although these results are very encouraging, there are 
clearly safety issues concerning the use of live vaccinia recombinant vaccines. Even 
though these authors used the attenuated Ankara strain of vaccinia 38 and stated the 
treatment was well tolerated with no adverse reactions, there are real concerns 
surrounding the release of such recombinant live virus vectors into the general 
population.  
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More recently a DNA-based HPV vaccine VGX-3100 has been developed 
which was delivered by 5 intramuscular injections combined with in vivo 
electroporation. This was initially used to treat 18 women with persistent CIN2/3 
which demonstrated a convincing immune response although efficacy was not 
reported in this study 39. A phase 2 trial has also been carried out using the same 
vaccine to treat a total of 148 women with CIN2/3 and CIN3 (Trial ID No. 
NCT01304524) although this has not yet reported.  
 
9. Pre-Clinical and Clinical Trials Carried out on Natural Products 
In addition to the previously discussed synthetic small-molecule, protein and vaccine 
based therapies, a variety of natural products have also been investigated for anti-
HPV activity 40. Examples of these are, ferulic acid 41, artemisinin 42-44, withaferin A 
45, resveratrol 46, (-)-epigallocatechin-3-gallate 47, ursolic acid 48, berberine 49, 
jaceosidin 50, curcumin 51 and indole-3-carbinol 52. Although all these products have 
shown activity against cultured HPV positive cervical carcinoma cell lines very few 
have been trialled in the clinic. Notable exceptions were:-  
• Oral administration of the artemisinin derivative Arteminol R for 28 days was 
shown to improve both clinical symptoms and disease marker expression in 10 
women with advanced cervical cancer with no serious adverse events 44.  
• Ninety eight women were recruited for a phase 2 randomised trial of placebo or 
800 mgs of orally administered green tea polyphenol (-)-epigallocatechin-3-gallate 
once daily for 4 months which showed no difference in CIN or HPV status 
between placebo or test 47.  
• Two hundred and eighty two HPV positive women with no dysplasia were treated 
with either a curcumin containing formulations or placebo controls for 30 days 
which showed a modest improvement in HPV clearance (87% Test Vs 73% 
placebo). 51. 
• Thirty women with biopsy confirmed CIN2/3 were randomised to receive 200 mg 
or 400mg of indole-3-carbinol or placebo orally once a day for 12 weeks. 
Although there was a statistically significant regression of dysplasia in the test 
group, there was no detectable clearance of HPV when compared to placebo 52. 
 
10. HHuman Imunodeficiency Virus IV Protease Inhibitors (HIV PI’s) Formatted: Font: Bold
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Most Human Imunodeficiency VirusHIV PI’s are small molecule, peptide mimetic 
drugs which target the HIV aspartyl protease that is essential for the production of 
infectious virions and these agents have been shown to have pleiotropic effects against 
viral replication at various stages of the virus life cycle 53. Futhermore, it was also 
shown that selective off-target effects of these drugs on the mammalian proteasome 
contributes to their activity against HIV 54-56. Since HPV, and many other viruses, are 
known to deregulate the proteasome 57, it was considered that HIV PIs may have 
broader activity against other viruses. Preclinical studies demonstrated this against HPV 
which showed lopinavir to be the most active HIV PI against cultured HPV positive 
cervical carcinoma cell lines 58. However, although lopinavir was the most effective 
HIV PI against HPV in vitro, this was at higher concentrations than can be achieved 
from normal oral dosing for HIV therapy 59. Indeed a recent comparison of non-PI and 
PI-based highly active antiretroviral therapy (HAART), both with and without oral 
lopinavir, was carried out in HIV positive women which showed no effect on the 
prevalence of cervical HPV infection 60. Nevertheless, previous in vitro studies have 
defined at least part of the mode-of-action of lopinavir against HPV61 and several HIV 
PI’s are now well known to have both anticancer and antiviral properties 62-66. 
Moreover, lopinavir has also been shown to have activity against severe acute 
respiratory syndrome (SARS) and, more recently, middle eastern respiratory syndrome 
(MERS) coronaviruses 67-69. 
Lopinavir is normally prescribed as a 4:1 mixture with ritonavir (Kaletra®) and earlier 
in vitro studies suggested that the presence of ritonavir may actually be detrimental to 
the anti HPV activity of this compound 58. Ritonavir as a mono-therapy has been shown 
to have anti-invasive and anti-proliferative activity against cells derived from pre-
invasive CINs but little activity against cells derived from more advanced cervical 
carcinomas 70.  
With regard to clinical trials carried out on treatment of HPV related cervical 
dysplasia with HIV PI’s, the University of Texas is currently recruiting for a phase II 
single-arm intervention trial of oral nelfinavir in patients with CIB 2/3 or 3 71 (Trial Id. 
No. NCT01925378) which is expected to complete in December 2016. A phase 1 
single-arm, proof-of-concept trial of topically applied Lopimune (Generic Kaletra, 
CIPLA) has also been carried out. Standard Lopimune soft- gelatin capsules (133.3mg 
Lopinvir + 33.3mg Ritonavoir)  were given twice daily as a vaginal pessary for 2 
weeks to 23 Kenyan women diagnosed with HPV positive HSIL 72. Follow up of 
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these women at 3 months showed 60% had regained normal pathology with 18% 
regressing to low-grade disease producing a combined positive response in 78% with 
clearance of HPV seen in 50% of these women.  Clearly, these observations support 
further investigation on the ability of HIV PI’s to treat HPV infection per se in 
addition to any associated dysplasia.  
 
 10. Expert Opinion 
TAs stated there is no clinically approved pharmacological treatment for HPV 
infection or associated cervical dysplasia and it is clear that .  Eexcisional swith 
surgery andor ablative procedures will continue to be the recommended treatment 
within opportunistic or organised screening programmes for pre-invasive disease as  
(illustrated in Figure 1) .   restricted for use with women diagnosed with high-grade 
disease (HSIL or CIN2/3) as illustrated in Figure 1.  
A potential new approach would be a ‘mass’ conservative medical effective treatment 
for HPV and associated disease. The problem is that HPV infection is very common, 
often producing no abnormal pathology and has a high rate of spontaneous clearance,  
most particularly in the early stages of disease and in low grade lesions and  in 
younger women aged <23 years 73. In view of this, a watch and wait policy is 
considered to be best clinical practice for the management of HPV infection and 
associated low-grade dysplasia (LSIL or CIN1) since excisional and ablative methods 
are necessarily destructive with the added risk of treatment associated side-effects and 
morbidity10, 11. Of particular concern is that in countries that do not have prophylactic 
vaccination or cytology screening, women and their partners who acquire, albeit 
transient, HR-HPV infection will constitute a reservoir of infectious virus which 
clearly enhances dissemination to other individuals. As discussed, the majority will 
clear the virus but the minority who develop persistent HPV infection are at increased 
risk of developing associated dysplasia. A potential solution to this problem would be 
a “catch-all” pharmacological antiviral treatment which also proved effective against 
dysplasia which may or may not be present. Such a treatment could then be prescribed 
on the basis of a positive test for HR-HPV with test-of-cure by repeat HPV testing. 
However, the rate of spontaneous clearance of HPV16/18 in placebo control groups 
can be  >70% within six weeks 51 which implies that such a pharmacotherapy would 
necessarily have to be extremely well tolerated with minimal risk of complications. 
This raises the question, are any of the previously discussed treatments suitable?  
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 Locally applied PDT, Cidofovir, Imiquimod, 5FU and Interferon all showed 
significant efficacy against dysplastic lesions although, all but Imiquimod, were 
physician applied.  Since there are also issues of safety, side-effects and cost it is 
unlikely that any of these modalities will ever be used for the treatment of HPV or 
pre-invasive disease.HPV infection in the absence of high grade dysplasia.  
With regard to therapeutic vaccines, there is no doubt that the physician 
applied vaccinia recombinant MVA-E2 proved extremely effective although there are 
very real safety concerns with this type of treatment which will undoubtedly limit its 
use. The DNA based vaccine VGX-3100 could provide the means to treat HPV 
infection per se although its efficacy is not yet known and, like all vaccinations, it is a 
systemic treatment with associated risks and the cost is currently unknown. 
A variety of preclinical studies have been carried out on the activity of 
different  phytochemicals in HPV positive cervical carcinoma cell lines although most 
of these do not translate into useful clinical efficacy. The possible exception to this 
could be Arteminol R  although this was only used to treat 10 women with advanced 
disease and clearly needs more thorough investigation. 
Finally, as regards off licence use of HIV PI’s,  the proof-of-concept trial on 
self-applied topical lopinavir (Kaletra) is a very promising indication but clearly 
needs larger phase 2 trials to establish efficacy. Most significantly, since Kaletra is 
currently licensed for the long-term systemic treatment of HIV positive pregnant 
women and children 74  it is comparatively safe when compared to the other 
previously discussed topical agents. As regards cost, the generic form of Kaletra 
(Lopimune) was approximately £15 per patient treated as purchased from a Kenyan 
pharmacy.    
In summary, in order for a it is very clear that an effective, inexpensive, non-
surgicalpharmacological treatment for HR-HPV and associated dysplasia to be 
implemented widely it would need to satisfy the following criteria:- 
• Be self-applied 
• Be non-destructive 
• Have minimal side-effects and be non-mutagenic 
• Have efficacy against HPV and associated dysplasia 
• Be affordable 
, self-applied treatment with minimal side effects would have great potential for the 
treatment of HPV and related cervical dysplasia most particularly in low resource 
settings. Out oOf the previously discussed treatmentsmodalities, it is our opinion that 
Formatted: Font: (Default) Times New Roman, 12 pt
Formatted: Font: (Default) Times New Roman, 12 pt
Formatted: Font: (Default) Times New Roman, 12 pt
Formatted: Font: (Default) Times New Roman, 12 pt
Formatted: Font: (Default) Times New Roman, 12 pt
Formatted: Bullets and Numbering
Formatted: Font: (Default) Times New Roman, 12 pt
Formatted: Indent: First line:  0 cm
 12 
low cost therapeutic vaccines or topical application of HIV protease inhibitors would 
areprovide the most promising candidate s to date.  
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